VYNE Therapeutics Inc. (VYNE) reported Q3 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $133.33 thousand.
VYNE Therapeutics Inc. (VYNE) reported Q3 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $133.33 thousand.